Central sensitization has major impact on quality of life in patients with axial spondyloarthritis

• Published in: Seminars in arthritis and rheumatism 2022-02, Vol.52, p.151933-151933, Article 151933
• Main Authors: Kieskamp, Stan C., Paap, Davy, Carbo, Marlies J.G., Wink, Freke, Bos, Reinhard, Bootsma, Hendrika, Arends, Suzanne, Spoorenberg, Anneke
• Format: Article
• Language: English
• Subjects: Axial Spondyloarthritis; Central Nervous System Sensitization; Central Sensitization; Female; Humans; Pain; Quality of Life; Spondylarthritis - complications; Spondylitis, Ankylosing - complications
• ISSN: 0049-0172; 1532-866X
• DOI: 10.1016/j.semarthrit.2021.11.006

Persistent pain has large potential impact on quality of life (QoL). During the course of the disease, many patients with axial spondyloarthritis (axSpA) report persistent pain. Central sensitization (CS) may explain part of this chronic pain. However, the role of CS in relation to QoL has been sparsely studied in axSpA. Therefore, our aim was to explore the relationship between CS and QoL in patients with axSpA. Consecutive outpatients from the Groningen Leeuwarden axSpA (GLAS) cohort completed the Central Sensitization Inventory (CSI; range 0–100) and the AS Quality of Life (ASQoL; range 0–18). Multivariable linear regression analysis was used to explore the relationship between CSI and ASQoL scores correcting for potential confounders. Of the 178 included axSpA patients, mean CSI score was 38.0 ± 14.1 and 45% scored ≥40, which indicates a high probability of CS. Mean ASQoL score was 6.0 ± 5.3 and mean ASDASCRP 2.1 ± 1.0. A CSI score ≥40 was significantly associated with higher ASQoL score (mean 9.7 vs. 3.3), higher ASDASCRP (mean 2.6 vs. 1.7), female gender (60% vs. 29%) and more often entheseal involvement (61% vs. 26%). In univariable analysis, CSI score explained a large proportion of the variation in ASQoL (B = 0.06, 95%CI: 0.05–0.07; R2=0.46). This association remained significant after correction for ASDASCRP, gender, entheseal involvement, comorbidities, symptom duration, smoking status, BMI class and educational level (B = 0.04, 95%CI: 0.03–0.05). CS is strongly related to patient-reported QoL in patients with axSpA independently from other patient- and disease-related aspects.